ClinicalTrials.gg
CompletedNCT01469052Updated Mar 26, 2012Results posted

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

A Phase 1 interventional study of AG-013736 and AG-013736 in Advanced Solid Tumors, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-26.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or histologically confirmed solid tumor(s) and with at least one site
  • Patients with adequate bone marrow, liver and kidney function
  • Patients with of at least 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Patients who have received chemotherapy, immunotherapy, radiotherapy or any agent within 4 weeks of study entry
  • Patients with have had a major surgical procedure within 4 weeks of study entry
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: AG-013736

  • Experimental
    Cohort 2

    Drug: AG-013736

  • Experimental
    Cohort 3

    Drug: AG-013736

  • Experimental
    Cohort 4

    Drug: AG-013736

  • Experimental
    Cohort 5

    Drug: AG-013736

  • Experimental
    Cohort 6

    Drug: AG-013736

Interventions

  • Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state

  • Axitinib continuous oral dosing (20 mg twice a day) in the fed state

  • Axitinib continuous oral dosing (5 mg twice a day) in the fed state

  • Axitinib continuous oral dosing (15 mg once a day) in the fed state

  • Axitinib continuous oral dosing (5 mg twice a day) in the fasted state

  • Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    MTD is defined as the dose level at which "no more than 1 of 6 participants experience dose-limiting toxicity (DLT) following de-escalation from the maximum administered dose (MAD)." DLT includes grade (Gr) 2 or greater gastrointestinal toxicities, Gr 3 anemia, nonhematological toxicities (excluding nausea, vomiting, and diarrhea) or Gr 4 neutropenia, thrombocytopenia and inability to resume axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.

    Time frame: Baseline up to Day 28

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours (hrs) post-dose on Day (D) 1 and 15 of Cycle (C) 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)

  3. Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)]

    AUC (0-12)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-12).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)

  4. Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)

  5. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)

  6. Maximum Observed Plasma Concentration (Cmax) in Fed State Versus Overnight Fasting

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)

  7. Time to Reach Maximum Observed Plasma Concentration (Tmax) in Fed State Versus Overnight Fasting

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)

  8. Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] in Fed State Versus Overnight Fasting

    AUC (0-24)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-24).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)

  9. Apparent Oral Clearance (CL/F) in Fed State Versus Overnight Fasting

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)

  10. Plasma Decay Half-Life (t1/2) in Fed State Versus Overnight Fasting

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)

07

Results

Posted Mar 26, 2012

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), FedCohort 2: Axitinib 20 mg BID, FedCohort 3: Axitinib 5 mg BID, FedCohort 4: Axitinib 15 mg QD, FedCohort 5: Axitinib 5 mg BID, FastedCohort 6: Axitinib 2 mg + 5 mg BID, Fasted
Started646686
Completed000100
Not completed646586
Withdrew: Adverse event230201
Withdrew: Progressive disease305372
Withdrew: Lack of efficacy000002
Withdrew: Moved to rollover protocol101001
Withdrew: Other010010

Outcome measures

PrimaryMaximum Tolerated Dose (MTD)

MTD is defined as the dose level at which "no more than 1 of 6 participants experience dose-limiting toxicity (DLT) following de-escalation from the maximum administered dose (MAD)." DLT includes grade (Gr) 2 or greater gastrointestinal toxicities, Gr 3 anemia, nonhematological toxicities (excluding nausea, vomiting, and diarrhea) or Gr 4 neutropenia, thrombocytopenia and inability to resume axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.

Time frame:
Baseline up to Day 28
Reported as:
Number · mg BID
Maximum Tolerated Dose (MTD)
mg BIDAll Treated Participants
Maximum Tolerated Dose (MTD)5
SecondaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours (hrs) post-dose on Day (D) 1 and 15 of Cycle (C) 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax)
Nanogram/milliliter (ng/mL)Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), FedCohort 2: Axitinib 20 mg BID, FedCohort 3: Axitinib 5 mg BID, FedCohort 4: Axitinib 15 mg QD, FedCohort 5: Axitinib 5 mg BID, FastedCohort 6: Axitinib 2 mg + 5 mg BID, Fasted
Day 1 (n= 6, 4, 6, 5, 8, 6)144.48 ± 73.9097.81 ± 89.9620.71 ± 9.4888.16 ± 84.9322.21 ± 34.8819.75 ± 17.95
Day 15 (n= 6, 3, 5, 6, 6, 6)130.91 ± 60.2394.75 ± 110.8128.68 ± 8.3367.08 ± 42.5051.82 ± 31.2152.24 ± 53.87
Day 29 (n= 4, 3, 5, 5, 7, 6)76.25 ± 67.8669.14 ± 103.1426.44 ± 17.2860.11 ± 103.7643.28 ± 41.4160.48 ± 29.10
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrCohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), FedCohort 2: Axitinib 20 mg BID, FedCohort 3: Axitinib 5 mg BID, FedCohort 4: Axitinib 15 mg QD, FedCohort 5: Axitinib 5 mg BID, FastedCohort 6: Axitinib 2 mg + 5 mg BID, Fasted
Day 1 (n= 6, 4, 6, 5, 8, 6)2.00 (1.00 to 4.00)4.04 (2.00 to 8.03)4.00 (1.00 to 4.08)2.05 (1.98 to 4.00)1.52 (0.50 to 4.00)1.01 (1.00 to 4.00)
Day 15 (n= 6, 3, 5, 6, 6, 6)3.00 (1.00 to 4.00)3.95 (2.08 to 4.05)2.00 (1.00 to 4.22)4.00 (2.00 to 11.83)1.01 (0.98 to 2.03)1.51 (0.98 to 4.00)
Day 29 (n= 4, 3, 5, 5, 7, 6)3.44 (0.00 to 4.03)4.13 (1.00 to 11.98)2.00 (1.00 to 4.00)3.50 (2.00 to 8.97)1.00 (0.50 to 4.02)2.01 (0.98 to 4.00)
SecondaryArea Under the Curve From Time Zero to 12 Hours [AUC (0-12)]

AUC (0-12)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-12).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)]
ng*hr/mLCohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), FedCohort 2: Axitinib 20 mg BID, FedCohort 3: Axitinib 5 mg BID, FedCohort 4: Axitinib 15 mg QD, FedCohort 5: Axitinib 5 mg BID, FastedCohort 6: Axitinib 2 mg + 5 mg BID, Fasted
Day 1 (n= 6, 4, 6, 5, 8, 6)692.47 (363.89 to 1317.76)564.56 (100.47 to 3172.37)88.62 (60.05 to 130.80)473.26 (162.59 to 1377.58)68.73 (29.84 to 158.34)61.92 (19.33 to 198.31)
Day 15 (n= 6, 3, 5, 6, 6, 6)793.89 (372.39 to 1692.48)485.52 (15.97 to 14760.66)130.57 (77.24 to 220.72)380.56 (161.49 to 896.80)126.25 (50.65 to 314.70)218.05 (81.21 to 585.47)
Day 29 (n= 4, 3, 5, 5, 7, 6)456.53 (98.07 to 2125.11)441.50 (19.51 to 9989.18)144.13 (66.74 to 311.24)377.86 (104.98 to 1360.02)126.08 (55.72 to 285.29)253.45 (127.21 to 504.96)
SecondaryApparent Oral Clearance (CL/F)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Reported as:
Geometric mean · Liter/hr (L/hr)
Apparent Oral Clearance (CL/F)
Liter/hr (L/hr)Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), FedCohort 2: Axitinib 20 mg BID, FedCohort 3: Axitinib 5 mg BID, FedCohort 4: Axitinib 15 mg QD, FedCohort 5: Axitinib 5 mg BID, FastedCohort 6: Axitinib 2 mg + 5 mg BID, Fasted
Day 1 (n= 6, 4, 6, 5, 8, 6)19.80 (9.14 to 42.87)30.82 (5.00 to 189.99)53.17 (35.99 to 78.55)29.04 (10.34 to 81.59)71.82 (31.26 to 165.04)30.27 (8.95 to 102.37)
Day 15 (n= 6, 3, 5, 6, 6, 6)18.82 (8.90 to 39.78)32.69 (2.80 to 381.94)38.29 (22.65 to 64.73)30.61 (11.26 to 83.23)39.05 (15.38 to 99.13)22.93 (8.54 to 61.57)
Day 29 (n= 4, 2, 5, 5, 7, 6)27.32 (8.35 to 89.42)18.82 (0.00 to NA)34.69 (16.06 to 74.91)31.07 (7.11 to 135.74)38.51 (16.66 to 89.02)19.73 (9.90 to 39.31)
SecondaryPlasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Reported as:
Mean · hr
Plasma Decay Half-Life (t1/2)
hrCohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), FedCohort 2: Axitinib 20 mg BID, FedCohort 3: Axitinib 5 mg BID, FedCohort 4: Axitinib 15 mg QD, FedCohort 5: Axitinib 5 mg BID, FastedCohort 6: Axitinib 2 mg + 5 mg BID, Fasted
Day 1 (n= 6, 3, 5, 5, 5, 4)3.09 ± 1.003.29 ± 1.862.31 ± 0.643.08 ± 0.971.86 ± 0.443.77 ± 1.60
Day 15 (n= 5, 3, 5, 4, 5, 6)5.20 ± 3.123.17 ± 1.712.22 ± 0.342.48 ± 0.682.01 ± 1.235.78 ± 6.33
Day 29 (n= 3, 2, 5, 3, 6, 6)6.11 ± 4.233.94 ± 2.652.78 ± 0.802.16 ± 0.793.03 ± 0.743.33 ± 0.90
SecondaryMaximum Observed Plasma Concentration (Cmax) in Fed State Versus Overnight Fasting
Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Reported as:
Geometric mean · ng/mL

No measurements were reported for this outcome.

SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) in Fed State Versus Overnight Fasting
Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Reported as:
Mean · hr

No measurements were reported for this outcome.

SecondaryArea Under the Curve From Time Zero to 24 Hours [AUC (0-24)] in Fed State Versus Overnight Fasting

AUC (0-24)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-24).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Reported as:
Geometric mean · ng*hr/mL

No measurements were reported for this outcome.

SecondaryApparent Oral Clearance (CL/F) in Fed State Versus Overnight Fasting

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Reported as:
Geometric mean · L/hr

No measurements were reported for this outcome.

SecondaryPlasma Decay Half-Life (t1/2) in Fed State Versus Overnight Fasting

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Reported as:
Geometric mean · hr

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Treated Participants—12/36 (33.3%)36/36 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventAll Treated Participants
DyspnoeaRespiratory, thoracic and mediastinal disorders2/36
ConvulsionNervous system disorders2/36
HaemoptysisRespiratory, thoracic and mediastinal disorders2/36
HypertensionVascular disorders2/36
DysphagiaGastrointestinal disorders1/36
PainGeneral disorders1/36
DehydrationMetabolism and nutrition disorders1/36
Cardiac arrestCardiac disorders1/36
Myocardial infarctionCardiac disorders1/36
Supraventricular tachycardiaCardiac disorders1/36
Most frequent other events
Showing 10 of 62
Most frequent other events
EventAll Treated Participants
HypertensionVascular disorders18/36
Decreased appetiteMetabolism and nutrition disorders17/36
FatigueGeneral disorders16/36
NauseaGastrointestinal disorders14/36
ConstipationGastrointestinal disorders12/36
HeadacheNervous system disorders12/36
DyspnoeaRespiratory, thoracic and mediastinal disorders11/36
VomitingGastrointestinal disorders10/36
DiarrhoeaGastrointestinal disorders9/36
ArthralgiaMusculoskeletal and connective tissue disorders7/36

Baseline characteristics

Age Continuous
Age Continuous(Years)Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), FedCohort 2: Axitinib 20 mg BID, FedCohort 3: Axitinib 5 mg BID, FedCohort 4: Axitinib 15 mg QD, FedCohort 5: Axitinib 5 mg BID, FastedCohort 6: Axitinib 2 mg + 5 mg BID, FastedTotal
Mean53.83 ± 8.7558.50 ± 4.8055.00 ± 7.2756.00 ± 9.4454.88 ± 7.9564.17 ± 10.0156.86 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), FedCohort 2: Axitinib 20 mg BID, FedCohort 3: Axitinib 5 mg BID, FedCohort 4: Axitinib 15 mg QD, FedCohort 5: Axitinib 5 mg BID, FastedCohort 6: Axitinib 2 mg + 5 mg BID, FastedTotal
Female44225320
Male20443316
08

Study locations

3 sites
  • Pfizer Investigational Site
    San Francisco, California 94115, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Madison, Wisconsin 53792, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Jul 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 7 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2011
First posted
Nov 10, 2011
Start
Nov 2002
Primary completionActual
Jul 2004
CompletionActual
Aug 2004
Results first posted
Mar 26, 2012
Last update
Mar 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01469052
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 10, 2011
Start date
Nov 2002
Primary completion
Jul 2004
Completion
Aug 2004
Results posted
Mar 26, 2012
Last update
Mar 26, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion